Nektar Therapeutics (NASDAQ:NKTR)

CAPS Rating: 2 out of 5

A biopharmaceutical company which develops breakthrough products that make a difference in patients' lives. It creates differentiated, innovative products by applying its platform technologies to established or novel medicines.

Recs

0
Player Avatar 4QCAPS (46.72) Submitted: 2/5/2012 8:31:11 PM : Outperform Start Price: $7.15 NKTR Score: -1.25

Total speculation on pain kill and cancer drug.

Featured Broker Partners


Advertisement